Drew Ranieri
Stock Analyst at Morgan Stanley
(1.27)
# 3,693
Out of 5,102 analysts
170
Total ratings
46.74%
Success rate
-11.39%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SIBN SI-BONE | Maintains: Overweight | $20 → $23 | $18.82 | +22.21% | 16 | Dec 2, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $70 → $100 | $88.88 | +12.51% | 14 | Dec 2, 2025 | |
| ATEC Alphatec Holdings | Maintains: Equal-Weight | $16 → $21 | $19.91 | +5.47% | 11 | Nov 10, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $4.77 | +25.79% | 4 | Mar 5, 2025 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $352.97 | +26.07% | 9 | Dec 2, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $14.05 | +92.17% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $2.91 | +174.91% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $21.76 | +1.10% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $16.48 | -51.46% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $4.29 | +1,823.08% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $22.14 | +71.64% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $84.45 | +13.68% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $11.83 | +119.78% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $200.43 | +47.18% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $127.25 | +120.04% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $7.42 | -32.61% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $18.90 | +270.37% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $547.36 | -45.19% | 6 | Apr 25, 2022 |
SI-BONE
Dec 2, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $18.82
Upside: +22.21%
Globus Medical
Dec 2, 2025
Maintains: Overweight
Price Target: $70 → $100
Current: $88.88
Upside: +12.51%
Alphatec Holdings
Nov 10, 2025
Maintains: Equal-Weight
Price Target: $16 → $21
Current: $19.91
Upside: +5.47%
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $4.77
Upside: +25.79%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $352.97
Upside: +26.07%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $14.05
Upside: +92.17%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $2.91
Upside: +174.91%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $21.76
Upside: +1.10%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $16.48
Upside: -51.46%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $4.29
Upside: +1,823.08%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $22.14
Upside: +71.64%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $84.45
Upside: +13.68%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $11.83
Upside: +119.78%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $200.43
Upside: +47.18%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $127.25
Upside: +120.04%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $7.42
Upside: -32.61%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $18.90
Upside: +270.37%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $547.36
Upside: -45.19%